Want to see GB:SVNS full AI Analyst Report?
Solvonis Therapeutics (SVNS) AI Stock Analysis
Top Page
Solvonis Therapeutics
(LSE:SVNS)
The score is primarily held down by weak financial performance—recurring losses, inconsistent recent revenue, and persistent cash burn—despite a comparatively low-debt balance sheet. Technicals add modest bearish pressure with price below key moving averages and a negative MACD, while valuation is difficult to assess due to a negative P/E and no dividend yield data.
Solvonis Therapeutics (SVNS) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 6.48M
- Dividend Yield
- ―
- Average Volume (3M)
- 30.62M
- Price to Earnings (P/E)
- -1.2
- Beta (1Y)
- 0.21
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- UK
- Employees
- 6
- Sector
- Industrials
- Sector Strength
- 63
- Industry
- Biotechnology
Solvonis Therapeutics Business Overview & Revenue Model
Company Description
Solvonis Therapeutics PLC focuses on the development of therapeutic solutions. The company is engaged in the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders focusing on addiction and psychiatr...
Solvonis Therapeutics Financial Statement Overview
Summary
Overall operating profile is high-risk: persistent operating and net losses (Income Statement score 12) and ongoing cash burn with worsening free cash flow in 2025 (Cash Flow score 22). The main offset is low leverage and positive, improving equity (Balance Sheet score 58), supporting near-term solvency despite weak returns.
Income Statement
12Very NegativeBalance Sheet
58NeutralCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 587.00K | 542.00K | 219.00K |
| Gross Profit | 0 | 0 | 0 | -134.00K | -51.00K | 55.00K |
| EBITDA | -5.74M | -5.74M | -1.38M | -2.94M | -2.59M | -900.00K |
| Net Income | -5.74M | -5.74M | -1.59M | -3.12M | -2.71M | -954.00K |
Balance Sheet | ||||||
| Total Assets | 7.58M | 7.58M | 3.20M | 2.43M | 4.94M | 3.13M |
| Cash, Cash Equivalents and Short-Term Investments | 1.72M | 1.72M | 757.00K | 155.00K | 1.64M | 598.00K |
| Total Debt | 75.00K | 75.00K | 0 | 34.00K | 22.00K | 950.00K |
| Total Liabilities | 1.39M | 1.39M | 119.00K | 408.00K | 385.00K | 2.32M |
| Stockholders Equity | 6.19M | 6.19M | 3.08M | 2.03M | 4.55M | 812.00K |
Cash Flow | ||||||
| Free Cash Flow | -3.27M | -3.27M | -1.13M | -1.47M | -3.08M | -255.00K |
| Operating Cash Flow | -3.27M | -3.27M | -1.13M | -1.24M | -2.36M | -254.00K |
| Investing Cash Flow | 0 | 0 | -337.00K | -232.00K | -718.00K | -1,000 |
| Financing Cash Flow | 4.23M | 4.23M | 2.08M | 0 | 4.13M | 800.00K |
Solvonis Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SVNS, the sentiment is Negative. The current price of 0.10 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.11, and below the 200-day MA of 0.19, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 43.11 is Neutral, neither overbought nor oversold. The STOCH value of 46.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:SVNS.
Solvonis Therapeutics Peers Comparison
Overall Rating
GB:IMI76Outperform
GB:AVG62Neutral
GB:SMIN61Neutral
GB:MGAM52Neutral
GB:MPAC45Neutral- GB:SVNS45Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:IMI | 76Outperform | GBP 6.75B | 21.01 | 32.41% | 1.23% | 7.67% | 45.97% |
| Sector * | 63Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
| GB:AVG | 62Neutral | GBP 280.68M | 38.38 | 5.57% | 0.66% | 4.43% | 2.67% |
| GB:SMIN | 61Neutral | GBP 7.39B | 4.29 | 92.97% | 1.80% | -33.55% | 4.29% |
| GB:MGAM | 52Neutral | GBP 721.44M | 39.19 | 5.79% | 4.67% | -5.58% | -32.73% |
| GB:MPAC | 45Neutral | GBP 102.70M | -13.84 | -10.45% | ― | 9.04% | 40.78% |
| GB:SVNS | 45Neutral | GBP 7.50M | -1.16 | -101.01% | ― | ― | ― |
* Industrials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:SVNS | Solvonis Therapeutics plc | 0.10 | -0.21 | -69.35% | |
| GB:AVG | Avingtrans plc | 760.00 | 274.48 | 56.53% | |
| GB:IMI | IMI plc | 2878.00 | 526.10 | 22.37% | |
| GB:MPAC | Mpac Group PLC | 341.50 | -33.50 | -8.93% | |
| GB:MGAM | Morgan Advanced Materials | 261.00 | 66.90 | 34.47% | |
| GB:SMIN | Smiths Group plc | 2697.00 | 209.93 | 8.44% |
Solvonis Therapeutics Corporate Events
Solvonis moves to add Portuguese sites to Phase 3 alcohol addiction trial
PositiveSolvonis Therapeutics has signed a Memorandum of Understanding with Portugal’s National Addiction Institute, ICAD, and local clinical partner Panegreen to assess adding Portuguese sites to MORE-KARE, its U.K. Phase 3 trial of ketamine-plus-ther...
Solvonis plans investor briefing as it advances pipeline in addiction and mental health
PositiveSolvonis Therapeutics, a London-based late clinical-stage biopharmaceutical firm listed on the LSE, develops small-molecule therapies for central nervous system disorders with a focus on addiction and mental health. Its pipeline includes advanced alc...
Solvonis boosts equity base with admission of over 1.09bn new shares
PositiveSolvonis Therapeutics has admitted 1,093,333,333 new ordinary shares to trading on the London Stock Exchange’s Main Market, increasing its total issued share capital to 7,899,736,826 shares, all carrying voting rights. The updated total voting...
Solvonis Advances CNS Pipeline as Cash Tightens and New Funding Arrives
NeutralSolvonis reported unaudited interim results for the six months to 30 June 2026, highlighting clinical progress on its CNS pipeline despite a widening cash constraint. The company is prioritising completion of Phase 3 for lead alcohol use disorder can...
Solvonis touts ketamine-based AUD candidate as data sharpen European and U.S. expansion plans
PositiveSolvonis Therapeutics plc, a London-listed biopharmaceutical company, is developing small-molecule therapies for central nervous system disorders, with a particular focus on addiction and psychiatric conditions. Its pipeline is led by AUD treatments...
Solvonis Wins Key European Patent for Next-Generation PTSD Drug SVN-114
PositiveSolvonis Therapeutics has secured a key intellectual property milestone, with the European Patent Office issuing a notice of allowance for a composition-of-matter patent linked to its PTSD lead candidate, SVN-114. The patent reinforces protection for...
Solvonis raises £1.3m to drive CNS pipeline and appoints new broker
PositiveSolvonis Therapeutics has conditionally raised £1.3 million via a discounted placing of 1,083,333,333 new shares, bringing a new UK institutional investor onto its register and appointing Turner Pope Investments as corporate broker. Admission of...
Solvonis Steps Up U.S. Investor Push With Water Tower Research Conference
PositiveSolvonis Therapeutics will showcase its CNS-focused drug pipeline and capital-efficient development strategy at the Water Tower Research Virtual Insights Conference on 22-23 September 2026. The event features a pre-recorded CEO fireside chat and inve...
Solvonis’ SVN-015 Cleared for Further NIDA Studies in Stimulant Use Disorder
PositiveSolvonis Therapeutics has reported encouraging initial preclinical data for its discovery-stage candidate SVN-015, a small molecule designed to modulate dopamine and serotonin transporters for the treatment of stimulant use disorder. The compound com...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026